Hypertension
Conditions
Interventions
Experimental group:Bevanolol hydrochloride tablets
Sponsors
The First Affiliated Hospital of He'nan University of Chinese Medicine
Eligibility
Sex/Gender
Male
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Male patients initially diagnosed with grade I-II essential hypertension according to the Diagnostic Criteria of the Chinese Guidelines for Hypertension Prevention and Treatment (2018 Revision); 2. Patients with essential hypertension requiring drug intervention; 3. Aged 30-65 years; 4. Married or cohabitant, with a fixed partner and relatively fixed frequency of sex; 5. There was no obvious clinical manifestation of erectile dysfunction (ED) before treatment; 6. The informed consent has been signed.
Exclusion criteria
Exclusion criteria: 1. Patients who had taken ED drugs before enrollment or planned to take them during the study; 2. Patients with abnormal development of external genitalia and anatomical malformations; 3. Previous history of spinal cord trauma, or other nerve injury or disease affecting sexual function; 4. Patients with uncontrolled diabetes or unstable blood sugar or diabetes complications; 5. Sequelae of cerebrovascular disease, severe cardiovascular diseases (such as cardiogenic shock, cardiac insufficiency, unstable angina, coronary syndrome, myocardial infarction, severe sinus bradycardia, Grade II type II and grade III atrioventricular block), pheochromocytoma, severe lung disease, pulmonary heart disease, hyperlipidemia, patients who have mental or psychological illness or need to be treated with other drugs; 6. Patients with abnormal liver and kidney function; The researcher considered that the patients were not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of International Erectile Function Scale (IIEF-5) scores before and after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of erectile dysfunction (ED);Effective rate of blood pressure control before and after treatment; | — |
Countries
China
Contacts
Public ContactLiu Xincan
The First Affiliated Hospital of He'nan University of Chinese Medicine
Outcome results
None listed